Animal Model News and Research

RSS

Over-expression of Stat5 protein leads to deadly spread of prostate cancer: Study

Researchers from the Kimmel Cancer Center at Jefferson have found that Stat5, a signaling protein previously found to be key to survival of prostate cancer, is also involved in metastasis.

20 May 2010

Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever

Inviragen has announced the initiation of the first clinical trial of its vaccine to protect against dengue fever. The trial, to be conducted at Saint Louis University, is designed to assess the safety of Inviragen's investigational dengue vaccine.

20 May 2010

Positive data from Geron's TAT153 small molecule telomerase activator in animal model of IPF

Geron Corporation today announced positive data on its orally available small molecule telomerase activator, TAT153, in an animal model of idiopathic pulmonary fibrosis (IPF). The data show that administration of TAT153 increased telomerase activity in the lung tissue, reduced inflammation, preserved functional lung tissue, slowed disease progression and attenuated loss of pulmonary function.

19 May 2010

Vect-Horus accentuates its leadership in delivering drugs to the central nervous system

Vect-Horus is a biotechnology company based on the scientific work of Dr. Michel Khrestchatisky and specializes in the development of peptide and pseudo-peptide-based vector molecules for drug targeting and delivery to the central nervous system (CNS).

18 May 2010

GRNCM1 do not cause cardiac arrhythmias after transplantation: Preclinical study

Geron Corporation today reported positive preclinical study data showing that GRNCM1, Geron's cardiomyocyte product derived from human embryonic stem cells, does not cause cardiac arrhythmias after transplantation into a model of chronic heart damage designed to test this potential safety concern.

14 May 2010

RYGB surgery increases insulin activity in diabetes mellitus patients

Diabetes mellitus is a chronic metabolic disease resulted from, either decreased production of insulin or increased resistance to it from peripheral tissues or both factors combined together. While medical treatment remains the mainstay of treatment for diabetes, some surgical procedures, such as Roux-en-Y gastric bypass, have demonstrated some potential to be a treatment option for diabetes.

13 May 2010

GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010

GTC Biotherapeutics, Inc. today reported its financial results for the first fiscal quarter ended April 4, 2010. The total net loss for the first quarter was $7.7 million, or $0.26 per share, compared to $10.4 million, or $0.99 per share, for the first quarter of 2009.

12 May 2010

Mutations in STRAD-alpha gene can cause PMSE syndrome in Amish children: Penn researchers

So often the rare informs the common. Penn researchers investigating a regulatory protein involved in a rare genetic disease have shown that it may be related to epileptic and autistic symptoms in other more common neurological disorders.

12 May 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.

11 May 2010

Progestins increase chances of cancer metastasizing: Study

After menopause, 6 to 10 million women take hormone therapies, which are often a combination of estrogen and progestin, to replace hormones lost from inactive ovaries. Progestin is a hormone that is used to counteract the potentially negative effects of estrogen therapy on the uterus. In studies sponsored by the National Institutes of Health, evidence has been found that estrogen and progestin in hormone therapies increase the risk of breast cancer in post-menopausal women.

7 May 2010

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced the presentation of data on its novel resolvins for the treatment of both ocular surface diseases and retinal diseases at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida, being held May 2-6, 2010.

7 May 2010

Multistage nanovector system for siRNA delivery lengthens therapeutic effects of ovarian cancer treatment

New research by scientists at The University of Texas Health Science Center at Houston (UTHealth) and The University of Texas M. D. Anderson Cancer Center could make it easier for patients to use a family of promising experimental cancer therapeutics known as small interfering RNA (siRNA).

6 May 2010

New data on Surfaxin LS presented at 2010 PAS Annual Meeting

Discovery Laboratories, Inc., announced that new data regarding Surfaxin LS (its novel, lyophilized KL4 surfactant dosage form) were presented at the 2010 Pediatric Academic Societies Annual Meeting. The two studies presented demonstrate that Surfaxin LS improves lung function and oxygenation while attenuating lung inflammation in the preterm lamb model of respiratory distress syndrome.

5 May 2010

UVA exposure at early age does not cause melanoma

Early life exposure to ultraviolet A light does not cause melanoma in a fish model that previously made that connection, scientists from The University of Texas MD Anderson Cancer Center reported today in the online Early Edition of the Proceedings of the National Academy of Sciences.

5 May 2010

Study: Parvovirus therapy offers complete regression of malignant brain tumors

Particular parvoviruses normally infect rodents, but they are also infectious for human cells. However, they do not cause any disease symptoms in humans. Most importantly, these viruses have an astonishing property: They kill infected tumors cells without causing any damage to healthy tissue.

5 May 2010

Amorfix Life Sciences detects AD-associated aggregated Beta-amyloid in blood plasma

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases such as Alzheimer's disease (AD), announced today the detection of the AD-associated aggregated Beta-amyloid (ABeta), the hallmark of AD, in the blood from the most-frequently-used animal model of AD. The assay detects both oligomeric and fibrillar aggregates of ABeta, which are generally considered to be the toxic forms and major contributors to brain dysfunction in AD.

4 May 2010

Researchers receive $250,000 to study inventive cell-transfer therapy to treat cortical dysplasia

University of Florida researchers will receive $250,000 to study an inventive cell-transfer therapy to treat cortical dysplasia, a condition where the brain develops abnormally before birth, causing severe epilepsy in children and adults.

4 May 2010

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced interim study results that showed its doxorubicin prodrug INNO-206 demonstrated statistically significant anti-tumor activity in human myeloma tumor cells growing in immune-deficient mice compared to a control group, while exhibiting significantly less toxicity than doxorubicin even though INNO-206 was administered at much higher doses.

3 May 2010

Preclinical safety data reports Natural S-equol has little effect on 2 reproductive hormones

Natural S-equol, a novel soy germ-based compound, is very likely the primary ingredient for reducing hot flushes in the dietary supplement SE5-OH, which is under development for reduction of menopause symptoms, according to pre-clinical efficacy data from studies using an animal model presented at the Experimental Biology 2010 annual meeting.

3 May 2010

Nitration and allergy

Food proteins are nitrated through various processes. Just how these processes affect food allergies, however, is only now coming to light. The latest findings of a research project funded by the Austrian Science Fund FWF are being presented today at an international symposium in Italy. The findings show that in the case of a particular food protein the nitrated form can trigger a stronger allergic reaction than the non-nitrated form. At the same time, however, this nitrated form of the protein is better digested and therefore rendered "harmless".

27 Apr 2010

Animal Model News and Research

Over-expression of Stat5 protein leads to deadly spread of prostate cancer: Study

Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever

Positive data from Geron's TAT153 small molecule telomerase activator in animal model of IPF

Vect-Horus accentuates its leadership in delivering drugs to the central nervous system

GRNCM1 do not cause cardiac arrhythmias after transplantation: Preclinical study

RYGB surgery increases insulin activity in diabetes mellitus patients

GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010

Mutations in STRAD-alpha gene can cause PMSE syndrome in Amish children: Penn researchers

Transition Therapeutics reports increased revenue in third-quarter 2010

Progestins increase chances of cancer metastasizing: Study

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Multistage nanovector system for siRNA delivery lengthens therapeutic effects of ovarian cancer treatment

New data on Surfaxin LS presented at 2010 PAS Annual Meeting

UVA exposure at early age does not cause melanoma

Study: Parvovirus therapy offers complete regression of malignant brain tumors

Amorfix Life Sciences detects AD-associated aggregated Beta-amyloid in blood plasma

Researchers receive $250,000 to study inventive cell-transfer therapy to treat cortical dysplasia

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

Preclinical safety data reports Natural S-equol has little effect on 2 reproductive hormones

Nitration and allergy

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News